CELIAC DISEASE AMONG CHILDREN PRESENTED WITH UNEXPLAINED SHORT STATURE

By

Mohamed Sayed Hemeda*, Ahmed Saad Eldeen Ibrahim*, Mohamed Sami Elhakim**, Kamel Soliman Hammad***

Pediatrics*, Pathology** and clinical Pathology*** departments, Faculty of Medicine, Al-Azhar University

ABSTRACT

Introduction: Celiac disease is a chronic autoimmune condition, in genetically susceptible persons, perpetuated by the ingested gluten from cereals, wheat and barley, its clinical spectrum is broad, varies from absence of symptoms to gastrointestinal (classic) and/or extra intestinal (non-classic) symptoms, patients without symptoms may have latent or silent celiac disease, because celiac disease can be atypical or even clinically silent, many patients remain undiagnosed and at risk for the long-term, sometimes serious complications of untreated celiac disease. Short stature is the most commonly encountered extra-intestinal (non-classical) symptoms of CD in children, being found in roughly one-third of all new pediatric celiac diagnoses, while it can be directly related to malabsorption of nutrients, it should completely reverse once a child is strictly adherent to Gluten free diet.

Aim of the work: The goal of this study was to screen for coeliac disease in Egyptian children with unexplained short stature by estimating serum level of total IgA and tissue transglutaminase IgA.

Methodology: Cross sectional analytical study for 100 child with short stature (males and females), attended the pediatric out-patient clinics of AL-Sayed Galal and Alhussen university hospitals in Cairo during the period from April 2017 to march 2019, any child aged 2-18 years with undetectable cause of short stature whose Z score for height was less than -2 SD for the age and sex according to the WHO charts (WHO, 2006), not previously screened for Celiac disease was enrolled in the study, after approval of his care-giver, the medical records of patients evaluated for short stature include a proper detailed history and physical examination, growth analysis, followed by radiological (bone age), and Laboratory screening (including celiac serological screening and Growth hormone evaluation), chromosomal analysis were performed when appropriate, followed by small intestinal biopsy for celiac seropositive patients and Growth hormone stimulation test was performed in suspected patients.

Results: The demographic characteristics of all 100 cases regarding mean age in months was 80.85 ± 33.55 with range 36 – 179, Sex distribution of all cases was 52 (52.0%) female and 48 (48.0%) male, mean height in cm for all cases was 102.04 ±
13.48 with range 84 – 141 and median height Z score for all study group was -3.4 (-3.6 – -3) with range -4.6 - -2.6.

The results showed that 11(11%) cases were positive for TTG IgA antibodies with normal level of total IgA identified celiac cases with mean age in months was 86.91 ± 37.58, female cases were 7 (63.6%) and 4 (36.4%) cases were males, mean Height in cm was 102.18 ± 14 and median height Z score was -3.6 (-4.3 – -3.4).

**Keywords:** Short stature; Celiac disease; Children; Anti-tissue transglutaminase antibody, Idiopathic short stature.

**INTRODUCTION**

Celiac disease is a chronic autoimmune condition, in genetically susceptible persons, perpetuated by the ingested gluten from cereals, wheat and barley.\(^1\)

Classic symptoms include gastrointestinal problems such as chronic diarrhea, abdominal distension, malabsorption, loss of appetite, and among children failure to grow normally. This often begins between six months and two years of age. Non-classic symptoms (eg, short stature, delayed puberty, epilepsy, peripheral neuritis and iron deficiency anemia) are the most common, especially in people older than two years.\(^2\)

The standard method of diagnosing celiac disease in symptomatic persons older than 2 years is the tissue transglutaminase (tTG) IgA test, followed by intestinal biopsy for histologic confirmation.\(^3\)

Short stature is the most commonly encountered extra-intestinal manifestation of CD in children, being found in roughly one-third of all new pediatric celiac diagnoses. While it can be directly related to malabsorption of nutrients, it should completely reverse once a child is strictly adherent to a Gluten free diet (GFD).\(^4\)

Around 2.5-3% of the children worldwide are short, 5 The Egyptian Demographic and Health Survey of 2008 (EDHS 2008) revealed that the prevalence of stunting among children under 5 was 28.9%\(^2\), while that of the EDHS 2014 was found to be 21% while the prevalence of stunting among children aged 1-12 years attending the outpatient Pediatric clinic of Al-Azhar University
Hospital (Al-Hussein), Cairo was 15.8%.

Endocrinological causes of short stature accounted for 26% while celiac disease (CD) constituted 6.6% of children with short stature in Egypt.

In Egypt celiac disease is a frequent disorder among children, both in the general population (0.53%) and in at-risk groups (6.4%).

The only known effective treatment is a strict lifelong gluten-free diet, which leads to recovery of the intestinal mucosa, improves symptoms, and reduced risk of developing complications in most people. If untreated it may result in cancers such as intestinal lymphoma and a slight increased risk of early death.

**Ethical consideration:**

1- The ethical committees of Al-Azhar faculty of medicine & pediatric department approved the study.

2- Informed consent was obtained from parents of all included children.

3- The research protocol did not interfere with any medical recommendations or prescriptions.

4- The aim of the study & all investigations as well as the risks & benefits of study have been explained to parents of the patients.

5- The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

6- All data of patients & results of study are confidential & patients have the right to keep it.

7- The patient has the right to withdraw from the study at any time.

**Financial Disclosure/Funding:**

The authors received no financial support for research, authorship, & or publication of this article.

**PATIENTS AND METHODS**

This study is a cross sectional study that was carried out on 100 children with short stature (males and females). The cases were attending the pediatric out-patient clinic off AL-Sayed Galal and Alhussen university hospitals in
Cairo, any child fulfilled the inclusion criteria was enrolled in the study after obtaining a written consent from the care giver during the period from April 2017 to March 2019.

**Inclusion criteria:**

1. Age 2 - 18 years with undetectable case of short stature whose Z score for height was < -2 SD for the age and sex according to the WHO charts.11
2. Not previously screened for Celiac disease.

**Exclusion criteria:**

- Short children with demonstrable cause such as:
  1. Familial and constitutional short stature.
  2. Chronic illness.
  3. Disproportionate short stature.
  4. Short stature of endocrinal origin (eg, growth hormone deficiency).
  5. Turner syndrome.
  6. Short stature with significant congenital anomalies.
  7. Patients on gluten free diet.

Each child enrolled in the study was subjected to the following:-

1) Prestructured questionnaire.
2) Anthropometric measurements.
3) Detailed history (eg: personal, dietetic, familial, gastrointestinal symptoms).
4) Complete physical examination.
5) Radiological investigation: Antero-posterior plain X-ray film of left wrist was taken, and bone age was determined according to Greulich and Pyle atlas.12

6) Laboratory investigations
   - Complete blood count by using cell counter (Diagon D cell 60, Hungary).
   - Liver ((SGOT, SGPT) and renal (Blood urea and creatine) using biochemical auto-analyzer (BT 1500, Rome, Italy)
   - Total serum IgA by nephelometry using a Behring BNII nephelometer (Dade Behring, Milton Keynes, UK). level below 10mg/dl considered deficient.13
   - IgA class serum human tissue transglutaminase antibody
CELIAC DISEASE AMONG CHILDREN PRESENTED WITH UNEXPLAINED SHORT STATURE

Mohamed Sayed Hemeda, Ahmed Saad Eldeen Ibrahim, Mohamed Sami Elhakim, Kamel Soliman Hanmad

(IgA-TTGA) by enzyme linked immunosorpant assay (ELISA):

**Used kits:** Enzyme-linked Immunosorbent Assay Kit for Tissue transglutaminase IgA (INOVA Diagnostics Inc., USA).

**Results:** The result was considered weak positive if the sample demonstrates 20–30U/ml or moderate to strong positive if the sample demonstrates >30U/ml.14

• **Thyroid profile:** TSH was estimated by immunoradiometric assay (IRMA), while FT3 and FT4 were estimated by radioimmunoassay kits from Diagnosis Product Corporation (Los Angeles, CA, USA).15

• **Growth hormone evaluation** (IGF-1 and growth hormone provocation test for cases with low level of IGF-1), **IGF-1** was determined at diagnosis using solid phase IRMA, using kits from Diagnostic System Laboratories Inc., Texas, USA. Patients were considered not to be GH deficient when the peak GH value during the stimulation test was equal to or higher than 7 ng/ml

• **KARYOTYPING** for all female patients with undetectable cause of short stature to exclude turner syndrome

7) **Upper gastrointestinal endoscopy for duodenal biopsy:** was done for the study group subjects who will have positive values on anti-tissue transglutaminase (IgA) antibody estimation, Four to six biopsy specimens were taken from the bulb and second parts of the duodenum. Formalin-fixed biopsy specimens stained with hematoxylin and eosin will be studied with the use of light microscopy, mucosal lesions were classified according to the criteria of modified Marsh (Dr. Michael Marsh introduced the classification system to describe the stages of damage in the small intestine as seen under a microscope).16

**Statistical analysis:**

Data were analyzed using IBM© SPSS© Statistics version 23 (IBM© Corp., Armonk, NY,
USA). Continuous numerical variables were presented as mean and standard deviation (SD). *

**RESULTS**

Our results are demonstrated in the following tables:

**Table (1): Age and sex distribution of all cases with unexplained short stature**

<table>
<thead>
<tr>
<th>Age (months)</th>
<th>Total cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ± SD</td>
<td>80.85 ± 33.55</td>
</tr>
<tr>
<td>Range</td>
<td>36 – 179</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>52 (52.0%)</td>
</tr>
<tr>
<td>Male</td>
<td>48 (48.0%)</td>
</tr>
</tbody>
</table>

**Table (2): celiac serological screening of studied population**

<table>
<thead>
<tr>
<th>Total IGA</th>
<th>Total cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>100 (100.0%)</td>
</tr>
<tr>
<td>deficient</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Tissue Transglutaminase IgA</td>
<td></td>
</tr>
<tr>
<td>positive</td>
<td>11 (11%)</td>
</tr>
<tr>
<td>Negative</td>
<td>89 (89%)</td>
</tr>
</tbody>
</table>

This table shows Celiac disease present in 11% of cases with unexplained short stature.
Table (3): Histopathological evaluation of celiac group

<table>
<thead>
<tr>
<th>Marsh classification of celiac group*</th>
<th>Celiac group no. = 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>2 (18.2%)</td>
</tr>
<tr>
<td>IIIA</td>
<td>3 (27.3%)</td>
</tr>
<tr>
<td>IIIB</td>
<td>6 (54.5%)</td>
</tr>
</tbody>
</table>

*Marsh II: Lymphocytic enteritis with crypt hyperplasia
Marsh IIIA: Partial villous atrophy
Marsh IIIB: Subtotal villous atrophy

Table (4): Intestinal and extra intestinal symptoms of celiac and non-celiac groups

<table>
<thead>
<tr>
<th>Gastro-intestinal symptoms</th>
<th>Non-celiac group</th>
<th>Celiac group</th>
<th>Test value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>1 (1.1%)</td>
<td>5 (45.5%)</td>
<td>34.11</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Vomiting</td>
<td>13 (14.6%)</td>
<td>4 (36.4%)</td>
<td>3.284</td>
<td>0.070</td>
<td>NS</td>
</tr>
<tr>
<td>Constipation</td>
<td>15 (16.9%)</td>
<td>6 (54.5%)</td>
<td>8.383</td>
<td>0.004</td>
<td>HS</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>8 (9.0%)</td>
<td>7 (63.6%)</td>
<td>22.93</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>1 (1.1%)</td>
<td>4 (36.4%)</td>
<td>25.59</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Hematemesis</td>
<td>1 (1.1%)</td>
<td>0 (0.0%)</td>
<td>0.125</td>
<td>0.724</td>
<td>NS</td>
</tr>
<tr>
<td>Oral ulcers</td>
<td>4 (4.5%)</td>
<td>2 (18.2%)</td>
<td>3.252</td>
<td>0.071</td>
<td>NS</td>
</tr>
<tr>
<td>Rectal prolapse</td>
<td>2 (2.2%)</td>
<td>1 (9.1%)</td>
<td>1.576</td>
<td>0.209</td>
<td>NS</td>
</tr>
<tr>
<td>Dental enamel hypoplasia</td>
<td>3 (3.4%)</td>
<td>3 (27.3%)</td>
<td>9.917</td>
<td>0.002</td>
<td>HS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skin symptoms</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Alopecia</td>
<td>2 (2.2%)</td>
<td>1 (9.1%)</td>
<td>1.576</td>
<td>0.209</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chest symptoms</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTHMA</td>
<td>11 (12.4%)</td>
<td>4 (36.4%)</td>
<td>4.424</td>
<td>0.035</td>
<td>S</td>
</tr>
<tr>
<td>Recurrent pneumonia</td>
<td>4 (4.5%)</td>
<td>0 (0.0%)</td>
<td>0.515</td>
<td>0.473</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skeletal symptoms</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rachitic symptoms</td>
<td>8 (9.0%)</td>
<td>4 (36.4%)</td>
<td>6.947</td>
<td>0.008</td>
<td>HS</td>
</tr>
<tr>
<td>Cong anomaly</td>
<td>2 (2.2%)</td>
<td>0 (0.0%)</td>
<td>0.252</td>
<td>0.616</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CNS symptoms</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Head ache</td>
<td>4 (4.5%)</td>
<td>2 (18.2%)</td>
<td>3.252</td>
<td>0.071</td>
<td>NS</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>5 (5.6%)</td>
<td>0 (0.0%)</td>
<td>0.651</td>
<td>0.420</td>
<td>NS</td>
</tr>
<tr>
<td>Hearing loss</td>
<td>2 (2.2%)</td>
<td>0 (0.0%)</td>
<td>0.252</td>
<td>0.616</td>
<td>NS</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>3 (3.4%)</td>
<td>0 (0.0%)</td>
<td>0.382</td>
<td>0.536</td>
<td>NS</td>
</tr>
</tbody>
</table>
This table shows that, the commonest gastrointestinal symptom in celiac group was chronic abdominal pain followed by chronic constipation then chronic diarrhea. Results showed highly significant difference in gastrointestinal symptoms in celiac cases compared to non-celiac cases in chronic abdominal pain, chronic diarrhea, chronic constipation, abdominal distention and dental enamel hypoplasia with P value (0.00).

**Table (5): Anthropometric measurements of celiac and non-celiac groups**

<table>
<thead>
<tr>
<th></th>
<th>Non-celiac group</th>
<th>Celiac group</th>
<th>Test value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>no. = 89</td>
<td>no. = 11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>Mean ± SD</td>
<td>102.02 ± 13.48</td>
<td>102.18 ± 14.14</td>
<td>-0.037*</td>
<td>0.971 NS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>84 – 141</td>
<td>84.5 – 129</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height z-score</td>
<td>Median (IQR)</td>
<td>-3.3 (-3.6 – -3)</td>
<td>-3.6 (-4.3 – -3.4)</td>
<td>-3.000≠</td>
<td>0.003 HS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>-4.1 – -2.6</td>
<td>-4.6 – -3.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (Kg)</td>
<td>Mean ± SD</td>
<td>17.99 ± 5.33</td>
<td>17.12 ± 5.8</td>
<td>0.505*</td>
<td>0.615 NS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>10.7 – 34</td>
<td>11 – 31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight z-score</td>
<td>Median (IQR)</td>
<td>-1.7 (-2.5 – -1.1)</td>
<td>-2.6 (-3.1 – -2.2)</td>
<td>-3.021≠</td>
<td>0.003 HS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>-3.5 – 1.2</td>
<td>-3.2 – -1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI Kg/M(2)</td>
<td>Mean ± SD</td>
<td>17.01 ± 2.08</td>
<td>15.97 ± 1.15</td>
<td>1.610*</td>
<td>0.111 NS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>14.1 – 24.2</td>
<td>14.9 – 18.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI z-score</td>
<td>Median (IQR)</td>
<td>0.6 (-0.3 – 1.4)</td>
<td>-0.1 (-0.4 – 0.6)</td>
<td>-1.681≠</td>
<td>0.093 NS</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>-2 – 5</td>
<td>-0.9 – 1.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head circumference (cm)</td>
<td>Normal</td>
<td>81 (91.0%)</td>
<td>11 (100.0%)</td>
<td>1.075*</td>
<td>0.300 NS</td>
</tr>
<tr>
<td></td>
<td>Microcephaly</td>
<td>8 (9.0%)</td>
<td>0 (0.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tunner stage</td>
<td>Normal</td>
<td>78 (87.6%)</td>
<td>9 (81.8%)</td>
<td>0.293*</td>
<td>0.588 NS</td>
</tr>
<tr>
<td></td>
<td>Delayed</td>
<td>11 (12.4%)</td>
<td>2 (18.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone age</td>
<td>Normal</td>
<td>70 (78.7%)</td>
<td>9 (81.8%)</td>
<td>0.059*</td>
<td>0.808 NS</td>
</tr>
<tr>
<td></td>
<td>Delayed</td>
<td>19 (21.3%)</td>
<td>2 (18.2%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This table shows highly significant difference in height Z score and weight Z score between celiac and non-celiac groups with P value (0.003).

Table (6): Comparison between celiac and non-celiac groups as regard C.B.C.

<table>
<thead>
<tr>
<th></th>
<th>Non-celiac group</th>
<th>Celiac group</th>
<th>Test value</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. = 89</td>
<td>No. = 11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hb Mean ± SD</td>
<td>10.01 ± 0.98</td>
<td>7.48 ± 0.85</td>
<td>8.159</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Range</td>
<td>7.9 – 12.1</td>
<td>6.4 – 8.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCV Mean ± SD</td>
<td>73.45 ± 5.5</td>
<td>57.45 ± 5.8</td>
<td>9.044</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Range</td>
<td>59 – 89</td>
<td>49 – 68</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCHC Mean ± SD</td>
<td>28.99 ± 2.43</td>
<td>23.55 ± 2.34</td>
<td>7.039</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>Range</td>
<td>24 – 34</td>
<td>21 – 29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>0.2 – 0.7</td>
<td>0.3 – 0.6</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table shows high significant difference in Hb, MCV and MCHC between celiac and non-celiac groups with P value (0.000).

Table (7): Growth hormone evaluation of celiac and non-celiac groups

<table>
<thead>
<tr>
<th></th>
<th>Total cases</th>
<th>Non celiac group</th>
<th>Celiac group</th>
<th>Test value*</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. = 100</td>
<td>No. = 89</td>
<td>No. = 11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ILGF1 Normal</td>
<td>79 (79.0%)</td>
<td>70 (78.7%)</td>
<td>9 (81.8%)</td>
<td>0.059</td>
<td>0.808</td>
<td>NS</td>
</tr>
<tr>
<td>Low</td>
<td>21 (21.0%)</td>
<td>19 (21.3%)</td>
<td>2 (18.2%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GH provocative test</td>
<td></td>
<td></td>
<td></td>
<td>21.000</td>
<td>0.000</td>
<td>HS</td>
</tr>
<tr>
<td>No</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td>0 (0.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal response</td>
<td>19 (90.5%)</td>
<td>19 (100.0%)</td>
<td>0 (0.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deficient</td>
<td>2 (9.5%)</td>
<td>0 (0.0%)</td>
<td>2 (100.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This table shows Cases of celiac disease with low level of ILGF-1 showed low level of GH after provocation test and diagnosed as Growth hormone deficiency, while non-celiac
group with low level of ILGF-1 showed normal GH response after provocation test and this consistent with ISS.

**Table (8): Marsh classification and level of Hb, ILGF-1, height and weight Z scores**

<table>
<thead>
<tr>
<th>Test</th>
<th>P-value</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILGF1</td>
<td>0.917*</td>
<td>0.632</td>
</tr>
<tr>
<td>Low</td>
<td>0 (0.0%)</td>
<td>1 (33.3%)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>-3.4 (-3.4--3.4)</td>
<td>-3.5 (-4.5--3.2)</td>
</tr>
<tr>
<td>Height z-score</td>
<td>-3.4 --3.4</td>
<td>-4.5 --3.2</td>
</tr>
<tr>
<td>Weight z-score</td>
<td>-2.6 (-2.7--2.5)</td>
<td>-2.2 (-3.1--1.9)</td>
</tr>
<tr>
<td>Weight (IQR)</td>
<td>-2.7 --2.5</td>
<td>-3.1 --1.9</td>
</tr>
<tr>
<td>HB</td>
<td>7.70 ± 1.56</td>
<td>8.13 ± 0.75</td>
</tr>
<tr>
<td>Range</td>
<td>6.6 -- 8.8</td>
<td>7.4 -- 8.9</td>
</tr>
</tbody>
</table>

This table shows no significant relation between level of Hb, ILGF-1, height and weight Z scores and MARSH classification.

**DISCUSSION**

This study is a cross sectional study that carried out on 100 children with proportionate short stature who attended the pediatric out-patient clinics of ALSayed-Galal and Alhussen university hospitals in Cairo, our objective was aimed to find out celiac disease among children presented with unexplained short stature.

The results showed that 11 (11%) cases from the total 100 (100%) cases with unexplained proportionated short stature were positive for Tissue
transglutaminase (TTG) IgA antibodies with normal level of total IgA identified as positive serological test for celiac disease with mean age in months was $86.91 \pm 37.58$ and range 48 – 168 and female cases were 7 (63.6%) and 4 (36.4%) cases were males.

Marsh classification for celiac cases was Marsh class II in 2 (18.2%) cases, IIIA in 3 (27.3%) cases and IIIB in 6 (54.5%) cases.

The low percentage of celiac cases may be related to wide range of age group of studied population (2-18years), low socioeconomic standard of most of studied population which contributed to lack of early medical advice and lack of specific nutritional institutions for celiac disease.

Our finding is consistent with other studies in Saudi Arabia and India, in Kingdom of Saudi Arabia studies showed that the percentage of celiac disease among children with short stature is approximately 10%, nearly 11% of patients presenting with short stature in India have coeliac disease, in these patients chronic diarrhea and anemia were significant predictors of coeliac disease, while in our study chronic abdominal pain and anemia were the significant predictors of celiac disease.

In Egypt a study by El Dayem et al., 2010 showed that celiac disease in non-endocrinal short stature account for (34.3%), these result agreed with De Lecea et al., 1996, who reported the percentage of CD in short children ranging from 25 to 33.8%. In 2017 a study by Hussein et al., for etiological factors of short stature in children and adolescents (experience at a tertiary care hospital) showed that celiac disease constituted 6.6% of children with short stature.

Our data revealed the demographic characteristics of all 100 cases with unexplained short stature regarding mean age in months $80.85 \pm 33.55$ with range 36 – 179 while mean age for celiac cases $86.91 \pm 37.58$ with range 48 – 168 and for non-celiac cases was $80.1 \pm 33.17$ with range 36 – 179, with no significant difference between celiac and non-celiac groups. The mean age for celiac group $86.91 \pm 37.58$ can be explained by the age of asking medical advice for children with short stature due to comparing with other children during entry the nursery or primary school.
A study by Savage et al identified the age of diagnosis of celiac disease to be 6 years for girls and 7 years for boys. 22

In Egypt a study by ELrefai et al, 2009 23 defined the average age for diagnosis of Celiac disease by 5.5 years, while another study El Dayem et al., 2010 16 defined the mean age for diagnosis of celiac disease in non-endocrinal short stature by 7.9 ± 3.9 years.

Sex distribution of all cases was 52 (52.0%) female and 48 (48.0%) male, while in celiac group 7 (63.6 %) female and 4 (36.4%) male and non-celiac group 45 (50.6 %) female and 44 (49.4%) male, with no significant difference between celiac and non-celiac groups.

A study by Rubio-Tapia et al., 2016 24 showed that the clinical presentation of celiac disease is not the same in men and women. The disease is not only more frequent in women than in men but is also more severe and more rapid.

In Egypt a study by Shehab, 2013 25 observed equal sex ratio among CD children.

There was significant decrease in celiac cases in height Z score with P value (0.003) and weight Z score with P value (0.003) compared to non-celiac group, these findings in celiac cases can be explained by the chronic malabsorption state affecting celiac cases which in turn results in various nutritional deficiencies of macro- and micronutrients such as minerals, vitamins, calories, dietary fiber and Hb.

A study Chishty, Singh, 2017 26 proved that the mean values of weight z-score, Height z-score and Hb were significantly lower in CD patients compared to non-celiac, another study by Eren, 2018 27 performed a comparison for anthropometric measurements in patients who were diagnosed at ≤ 6 years of age and > 6 years of age and proved that the height and weight z-scores of the patients who were diagnosed at > 6 years of age were significantly lower than the younger group which mean the celiac disease is a progressive chronic malnutrting disease and only the Gluten free diet (GFD) compliance will positively affect the patients’ all growth parameters.
Bone age for all cases was normal in 79 (79.0%) cases and delayed in 21 (21.0%) cases, in celiac cases bone age delayed in 2 (18.2%) cases and normal in 9 (81.8%) cases while in non-celiac cases normal bone age found in 70 (78.7%) and was delayed in 19 (21.3%).

Celiac disease can be complicated by metabolic bone diseases like osteoporosis, secondary hyperparathyroidism, and osteomalacia even without gastrointestinal complaints, these bone disorders explained by both local and systemic mechanisms started with calcium malabsorption due to mucosal atrophy, therefore, to avoid hypocalemia parathyroid hormone increases substantially (secondary hyperparathyroidism) and stimulates osteoclasts mediated bone degradation, calcium is then obtained from the skeleton reservoir, but this high remodeling state can lead to osteopenia and osteoporosis, altering bone microstructure and increasing fracture risk. 28

In celiac group 2 (18.2%) cases had delayed bone age diagnosed later with dealing with a short child must be the exclusion of CD, which may be responsible for growth failure. In particular, before evaluating Growth Hormone (GH) secretion in a short child in whom GHD is suspected on the basis of auxological data, CD must be excluded since false GH responses to pharmacological stimuli have been observed, followed by their normalization after starting a GFD. Moreover, Insulin-like growth factor I (IGF-I), which is considered to be the main peripheral GH mediator, is low in patients with insufficient GH secretion, but is not a discriminating factor in the evaluation of GH secretion, since its level is influenced also by the subject’s nutritional status. Low levels of insulin-like growth factor 1 and Insulin-Like Growth Factor Binding Protein (IGFBP) have been reported in patients with CD. 29

In non-celiac group 19 (21.3%) cases had delayed bone age and low level of IGF-1 with normal Growth Hormone level on provocation test, these cases diagnosed as Idiopathic short stature (ISS).

Tanner staging for all cases was normal in 87 (87.0%) cases and delayed in 13 (13.0%) cases,
in celiac cases only 2 (18.2%) cases had delayed tanner staging, aged 11 years (male with tanner stage I) and 14 years (female with tanner stage II) and 11 (12.4%) cases in non-celiac cases had delayed tanner staging.

The clinical findings can be explained by the lack effect of CD, deficient ILGF-1 and growth hormone in the development of secondary sexual characters. Delayed puberty affecting roughly 10% of newly pediatric celiac patients, delayed puberty is defined by lack of physical or hormonal signs of puberty at the age of usual onset. Visible secondary sexual development usually begins when girls achieve a bone age of 11 years and boys achieve a bone age of 12 years. In girls, a lack of breast development by 13 years, or a lack of menarche within three years after breast development or by 16 years is considered to be abnormal. For boys, no testicular enlargement by 14 years or a delay in development for five years or more after onset of genitalia enlargement is considered abnormal. In the case of CD, this delay in puberty is directly related to malabsorption, malnutrition and the disruption of the hypothalamic control of growth hormone secretion which should be resolved on a GFD, which should prevent any long-term complications and restore normal maturation.30

The commonest gastrointestinal symptom in celiac group was chronic abdominal pain 7 (63.6%) cases followed by chronic constipation 6 (54.5%) cases and only chronic diarrhea present in 5 (45.5%) cases, Rectal prolapse found in one female case aged 11ys. Results showed significant increase in the percentage of gastrointestinal symptoms in celiac cases compared to non-celiac cases in chronic abdominal pain with P value (0.000), chronic diarrhea with P value (0.000), chronic constipation with P value (0.004), abdominal distention with P value (0.000) and dental enamel hypoplasia with P value (0.002), chronic diarrhea in celiac disease is due to the maldigestion and malabsorption of nutrients. The stools might be watery or semi formed, light tan or gray and oily or frothy. The stools have a characteristic foul odour. In
infants and young children, malabsorption of ingested fat (steatorrhea) results in the delivery of excessive dietary fat to the large bowel. This results in the production of hydroxy fatty acids by bacteria, which causes secretion of fluids into the intestinal lumen.

Celiac disease causes damage to the intestinal villi that are responsible for absorbing nutrients, as food travels through the digestive tract, the intestinal villi are unable to fully absorb nutrients and may often absorb extra moisture from the stool instead. This leads to hardened stool that is difficult to pass, resulting in constipation.

Chronic abdominal pain in celiac disease is common and maybe explained by the affection of intestinal microbiota on the complex gut-brain axis along with the enteric nervous system, immune system and external environment, and alterations in this axis predispose to chronic pain in celiac disease, maldigestion and bloating can cause abnormal swelling and feeling of a full or tight abdomen and accompanied by abdominal pain. 31 Rectal prolapse in celiac disease occurred as a result of chronic constipation and increased of intra-abdominal pressure with weak pelvic floor muscles, 32 these findings consistent with findings of Guandalini and Discepolo, 2016 study. 33

Results showed significant increase in the percentage of extra-intestinal symptoms in celiac cases compared to non-celiac cases in asthma with P value (0.035) and rachitic symptoms with P value (0.008), The frequency of asthma increases in celiac patients, possibly due to common genetic or environmental factors contribute to the risk for both and nutritional deficiencies occurring due to celiac may help incite asthma. 34

Rickets in celiac disease is explained by the loss of villous architecture leads to malabsorption of calcium and vitamin D leading to hypocalcemia and secondary hyperparathyroidism. In addition, the release of proinflammatory cytokines, activating osteoblast represents the main locally acting mechanisms responsible for bone derangement, this result agreed
with the study by Assiri et al., 2016. 35

The exact mechanism by which CD leads to headaches is unclear, but it is speculated that it may be secondary to a lack of vitamins, macro elements, such as magnesium, low levels of serotonin, which are the direct result of the celiac associated malabsorption. An alternate hypothesis is that the impaired immune response results in an imbalance of pro-inflammatory cytokines in response to ingested gluten, leading to altered vascular tone, and subsequently, the onset of the headache. 27

While alopecia has an association with pediatric CD, it is one of the less common extra-intestinal manifestations seen, occurring in roughly 1% of patients. It is presumed to occur through an autoimmune reaction involving T-cell dysregulation and autoantibodies directed against anagen-stage hair follicle structures and a direct association with the human leukocyte antigen (HLA)-DQB1*0201 allele, these results consistent with the study done by Laurikka et al., 2018. 36

Lower levels of mean hemoglobin concentration, MCV and MCHC were more prominent in celiac group than non-celiac group with P value (0.000) for all means, and this can be explained by (1) iron is predominantly absorbed in the first portion of the small bowel, the duodenum, which is the main portion of the bowel affected by CD resulting in duodenal inflammation which subsequently leads to the malabsorption of iron and resultant iron-deficiency anemia, (2) occult blood loss in the gastrointestinal (GI) tract, occult gastrointestinal bleeding was detected in 25% to 54% of patients with CD, depending on the degree of villous atrophy, (3) Anemia of chronic disease, defined by anemia with high ferritin levels and inflammatory syndrome, has been also described in CD, associated aplastic anemia has also been reported in isolated cases. Vitamin B12 deficiency was considered theoretically to be less common in CD, as its absorption takes place in the terminal ileum, which is infrequently involved. However, studies have reported significant proportions for B12 deficiency also, 37 these finding
consistent with the study in Egypt done by Abd El-Shaheed et al., 2018. 38

The level of ILGF-1 for all cases was normal in 79 (79.0%) cases and low in 21 (21.0%) cases, but in celiac group 2 (18.2%) cases showed low level and in non-celiac group 19 (21.3%) cases showed low level, these results contrasted with other study done by Giovenale et al., 2006 39 who found that 0.23% of celiac cases had GH deficiency and these children did not grow after 1 year of GFD

Cases of celiac disease with low level of ILGF-1 showed low level of GH after provocation test and diagnosed as Growth hormone deficiency, while non-celiac group with low level of ILGF-1 showed normal GH response after provocation test and this consistent with ISS.

The presence of anti-pituitary autoantibodies (AAPs) is reported in children with CD and GH deficiency, Iughetti et al., 2006 40 found four out of five CD children with GH deficiency that resulted positive at high titers for AAPs, they also detected the presence of both anti-pituitary and anti-hypothalamus antibodies in seven CD children who did not show catch up growth after at least 12-months on a GFD, suggesting an autoimmune involvement between the two entities, and these findings agreed with Nardecchia et al., 2019. 41

**CONCLUSION**

• Celiac disease is important cause for unexplained short stature

• Celiac disease could be associated with GH deficiency

**RECOMMENDATIONS**

1. Paediatricians and other health care professionals should strive to make celiac disease screening readily available to all children with short stature within their community, especially for those infants most at risk.

2. Educational programs focused on non-classic presentation of celiac disease.

3. All short stature children should be screened for celiac disease whether they are males or females, had GIT symptoms or not, had delayed or normal bone age and had already diagnosed cause for short stature or not.

4. Idiopathic short stature should be considered in cases with low
level ILGF-1 and normal Growth hormone stimulation test.

**STUDY LIMITATIONS**

The current study had the following limitations:

- The results were from a single medical Centre.
- The sample size was rather small.
- Refusal of some patients to enter the study.

**REFERENCES**


10. Lebwohl, Benjamin, Jonas F. Ludvigsson, and Peter HR Green. (20150: "Celiac disease and non-


22. Savage MO, Backeljauw PF, Calzada R, Cianfarani S, Dunkel L, Koledova E, et al. (2016): Early detection, referral, investigation, and


34. Yavuzyilmaz, F., Ozdogan, S., Urganci, N. and Usta, M.K., (2019): Frequency of Asthma and Atopic Diseases in Inflammatory Bowel Disease and Celiac Disease. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP,


Extraintestinal manifestations of celiac disease: Early detection for better long-term outcomes. Nutrients, 10(8), p.1015.


المرض القللي (السيلياك) في الأطفال الذين يعانون من قصر قامه غير معلوم السبب

محمد سيد حميدة - أحمد سعد الدين إبراهيم منصور - محمد سامي الحكيم - كامل سليمان حماد

قسم طب الأطفال – كلية الطب – جامعة الأزهر
قسم الباثولوجيا العامة – كلية الطب – جامعة الأزهر
قسم الباثولوجيا الإكلينيكية – كلية الطب – جامعة الأزهر

الهدف من الدراسة:
دراسة المرض القللي (السيلياك) في الأطفال المصابين بقصر قامه غير معلوم السبب.

مواد وأسلوب الدراسة

الاعتبارات الأخلاقية:
تمت الموافقة على الدراسة من جانب لجنة الأخلاقيات بكلية طب الأزهر بنين بالقاهرة. وتم الحصول على موافقة مكتوبة باللغة العربية من جميع المشاركين. وتضمنت هذه الموافقة كـكل تفاصيل الدراسة (العنوان، الأهداف، الأساليب، الفوائد المتوقعة وخصوصية البيانات).
تصميم الدراسة:

هذه الدراسة دراسة مقطعية.

الأشخاص المستهدفين والمدة:

أجري هذا البحث على مائة طفلة وطفلة يعانون من قصر القامة الغير مفسر، تم اختيارهم من عيادات الأطفال الخارجية بمستشفى سيد جلال ومستشفى الحسين الجامعي.

المعايير الأثنتي:

معايير الاشتمال:

• قصر القامة الغير مفسر.

معايير الاستبعاد:

• الأطفال الذين يعانون من قصر القامة المفسر.
• الأطفال الذين سبق تشخيصهم بمرض بمرض السيلياك.

تم تجميع البيانات عن طريق:

1- موافقه كتابية من القائم على رعاية الطفل.
2- الإجابه علي استبيان منظم مسبق.
3- أخذ التاريخ الطبي المتعلق بالطفل تفصيليا.
4- القياسات المختلفة لكل طفل مسن ناحية الطول والوزن ومؤشر الكتلة الجسدية وتناسبات أطوال الجسم.

5- الفحص الطبي الشامل مع التركيز على وجود أي أعراض متعلقه بالجهاز الهضمي.

6- التركيز على وجود أي أعراض ناجمة عن الخلل السورائي ليتم استبعادها.

7- عمل أشعة سينية على الرسغ الأيسر.

8- فحص عينة من الدم الوريدى لعمل صورة دم كاملة وقياس وظائف الكلى والكبد.

9- عمل وظائف الغدد الدرقية.

10- قياس نسبة عامل النمو-شبيه الإنسولين-1 للإستدلل على هرمون النمو مع عمل اختبار تجئي للهرمون النمو عند الاشتباه في نقص هرمون النمو.

11- فحص عينة من الدم الوريدى لمستوى الأجسام المضادة ج. الكليه ومستوى الأجسام المضادة A للإنزيم ناقل الغلوتامين.

12- التصوير الصبغي الكروموموسومي للاطفال الإناث.
CELIAC DISEASE AMONG CHILDREN PRESENTED WITH UNEXPLAINED SHORT STATURE
Mohamed Sayed Hemeda, Ahmed Saad Eldeen Ibrahim, Mohamed Sami Elhakim, Kamel Soliman Hanmmed

13 - التنظیم العلوی للجهاند الهدم مم اخز عینات من
الانتی عشر للاطفال ذوي المدلل الایجابي للأجسام المضاة أ
للإنزیم ناقل الغلوتامین.

وكانت النتائج كالآتي:

- متوسط عمر الاطفال بالشهر موضوع الدراسة (85,85
± 33,55) و متوسط الطول (102.04 ± 13.48).

- خلال الدراسة تبين أن عدد الأطفال المصابين بقصر القامة
نتيجة الإصابة بمرض السيليياك يصل ال 11%.

- يتراوح متوسط عمر الاطفال بالشهر اطفال المصابين
بمرض السيليياك (91 ± 37.58) و متوسط الطول
(102.18 ± 14.14).

- تعدد الام ابطن اشهر اعراض الجهاز الهدمي المنتشر بـ
الأطفال موضوع الدراسة المصابين بمرض السيلياك وياتي
باعدها الامساك ثم الاسهال.

- بعض حالات الأطفال المصابين بمرض السيلياك قد
تكون مصاحبة لنقص في افراد هرمون النمو.

- خلال الدراسة تبين ان عدد الأطفال المصابين بقصر القامة
مع نقص في عاملم النمو شبيه الانسولين -1 مع استجابه
طبيعية لتحفيز هرمون النمو يمثل 19%.
وخلصت الدراسة إلى ما يلي:

- بمرض بمراض السيلياك من الأسباب المهمة لقصر القامة

الغير المفسر في الأطفال.

وقد أوصت الدراسة بالآتي:

1- ضرورة أن يكشف الأطباء وغيرهم من العاملين في الرعاية الصحية من أجل توفير الفحوصات الازمة بمراض السيلياك) للأطفال المصابةين بقصر القامة في محيطهم

وبخاصة لذوي الاحتياج الخاص له.

2- أهمية التوعية عن الاعراض الغير النمطيه بمرض السيلياك.

3- يجب عمل الفحوصات الخاصة بمرض بمراض السيلياك للأطفال المصابةين بقصر القامة مع عدم الاعتبار للجنس أو الاعراض أو العمر العظيمي.

4- قصر القامة مجهول السبب يجب اكتباره في حالات قصر القامة مع نقص في عامل النمو شبيه الإنسولين.1 مع إستجابة طبيعية لتحفيز هرمون النمو ويحتاج إلى التشخيص بواسطة التحليل الجيني.